Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

BACKGROUND: Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzaferro, Vincenzo, El-Rayes, Bassel F., Droz dit Busset, Michele, Cotsoglou, Christian, Harris, William P., Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P., Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, Shaib, Walid L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/
https://www.ncbi.nlm.nih.gov/pubmed/30420614
http://dx.doi.org/10.1038/s41416-018-0334-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/
https://www.ncbi.nlm.nih.gov/pubmed/30420614
http://dx.doi.org/10.1038/s41416-018-0334-0

Ejemplares similares